MI-INTEVA-PRODUCTS
5.10.2017 17:02:03 CEST | Business Wire | Press release
Inteva Products, a leading global Tier One automotive supplier of engineered components and systems, is pleased to announce three recent appointments that strengthen its executive leadership team in Europe. Inteva has 15 manufacturing and R&D development sites in eight countries across Europe, serving automakers with roof systems, interior systems, closure systems, motors and electronics.
Andrés Keve, Executive Director, Roof Systems
Keve joined Inteva in June as the executive in charge of the global Roof Systems product line.
Keve was previously Vice President, Business Unit Aftermarket for Huf Hulsbeck & Furst GmbH & Co. KG, where he had also served as Vice President for Global Sales, reporting to the Board. Prior to those assignments, he had similar experiences at Lear Corporation GmbH, A.T. Kearney GmbH and United Technologies Automotive GmbH.
Keve earned his Master of Business Administration (MBA) at NIMBAS Graduate School of Management/University of Bradford, Netherlands and UK, and his Mechanical Engineering degree from Aachen University (RWTH). Andres is fluent in German, English, and Spanish.
Jose Teixeira, Executive Director of Quality
Teixeira joined Inteva on October 1. As Executive Director of Quality, he will lead Inteva’s efforts to execute and improve our global quality systems.
Teixeira brings to Inteva more than 25 years of global manufacturing leadership experience. Most recently, he served as Global Corporate Quality Director for Ficosa International. During his tenure with Ficosa, he also held positions as interim CEO, North Africa; COO, North America; General Manager, Berne, Ind. plant; and Plant Manager, Maia, Portugal. Prior to joining Ficosa, Teixeira was General Manager and Plant Manager at Simoldes Plasticos. He previously held positions with Fhest SGPS, Philips Consumer Electronics and Renault/Nissan.
Teixeira has a Master in Electronics and Telecommunications degree from the University of Aveiro, in Aveiro, Portugal, and a Master of Business Administration degree from the Institute of Science and Innovation in Mechanical and Industrial Engineering, Porto, Portugal. He is fluent in English, Spanish, French and Portuguese.
Patrick Stewart, Vice President, General Manager Europe
Stewart began this new assignment in June. Since Inteva’s founding in 2008 until this assignment, he had served as Inteva’s Vice President & Executive Director, Interior Systems, with global responsibility for the Interior Systems product line. Prior to 2008, Stewart held a wide variety of assignments at Delphi and other suppliers. Previous positions included Launch Manager; Manager, Global Product Engineering, Interior Systems; and Chief Engineer of Interior Systems & Cockpits.
Stewart earned a Bachelor of Science degree in Chemical Engineering from the University of Dayton (Ohio) and a Master of Science degree in Engineering Science from Rensselaer Polytechnical Institute in Troy, New York. He is a graduate of Delphi’s Lean College and has attended leadership training at the Center for Creative Leadership. Stewart is a Six Sigma Green Belt with extensive training in statistical quality and process control.
All three executives report directly to Lon Offenbacher, Inteva CEO & President; all are based in Dietzenbach, Germany.
About Inteva Products, LLC
Inteva Products, LLC is a leading global automotive supplier providing automakers with innovative, reliable, environmentally friendly products that enhance vehicle quality, safety and performance. Inteva has global resources for engineering, manufacturing and customer service for Closure Systems, Interior Systems, Motors and Electronics, and Roof Systems. Formed in 2008, the tier-one supplier is focused on achieving sustained global growth, providing excellent customer service and driving innovation. Inteva was founded on in novative solutions and the use of applied te chnology to drive va lue-based solutions. Inteva employs more than 15,000 people globally and is headquartered in Troy, Michigan USA.
For future company updates, please visit the Inteva Products website , or the company’s Facebook , LinkedIn and Twitter pages.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171005005915/en/
Contact:
Inteva Products
Karen Manardo
248-535-4825
kmanardo@intevaproducts.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom